全文获取类型
收费全文 | 4199篇 |
免费 | 114篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 71篇 |
妇产科学 | 26篇 |
基础医学 | 154篇 |
口腔科学 | 82篇 |
临床医学 | 573篇 |
内科学 | 1246篇 |
皮肤病学 | 93篇 |
神经病学 | 152篇 |
特种医学 | 90篇 |
外科学 | 414篇 |
综合类 | 219篇 |
预防医学 | 382篇 |
眼科学 | 53篇 |
药学 | 618篇 |
中国医学 | 65篇 |
肿瘤学 | 59篇 |
出版年
2024年 | 11篇 |
2023年 | 113篇 |
2022年 | 156篇 |
2021年 | 208篇 |
2020年 | 192篇 |
2019年 | 190篇 |
2018年 | 183篇 |
2017年 | 116篇 |
2016年 | 69篇 |
2015年 | 55篇 |
2014年 | 208篇 |
2013年 | 196篇 |
2012年 | 145篇 |
2011年 | 171篇 |
2010年 | 154篇 |
2009年 | 137篇 |
2008年 | 111篇 |
2007年 | 104篇 |
2006年 | 92篇 |
2005年 | 66篇 |
2004年 | 35篇 |
2003年 | 48篇 |
2002年 | 39篇 |
2001年 | 30篇 |
2000年 | 20篇 |
1999年 | 25篇 |
1998年 | 16篇 |
1997年 | 24篇 |
1996年 | 15篇 |
1995年 | 13篇 |
1994年 | 11篇 |
1993年 | 9篇 |
1992年 | 9篇 |
1990年 | 7篇 |
1988年 | 7篇 |
1987年 | 8篇 |
1986年 | 7篇 |
1985年 | 63篇 |
1984年 | 132篇 |
1983年 | 151篇 |
1982年 | 120篇 |
1981年 | 113篇 |
1980年 | 119篇 |
1979年 | 112篇 |
1978年 | 118篇 |
1977年 | 55篇 |
1976年 | 102篇 |
1975年 | 81篇 |
1974年 | 92篇 |
1973年 | 68篇 |
排序方式: 共有4333条查询结果,搜索用时 46 毫秒
41.
42.
43.
I. Aiza-Haddad A. Ballesteros-Amozurrutia O.D. Borjas-Almaguer M. Castillo-Barradas G. Castro-Narro N. Chávez-Tapia R.A. Chirino-Sprung L. Cisneros-Garza M. Dehesa-Violante J. Flores-Calderón A. Flores-Gaxiola I. García-Juárez M.S. González-Huezo E.I. González-Moreno F. Higuera-de la Tijera D. Kershenobich-Stalnikowitz E. López-Méndez R. Malé-Velázquez F. Bosques-Padilla 《Revista de gastroenterologia de Mexico》2018,83(3):275-324
The aim of the Mexican Consensus on the Treatment of Hepatitis C was to develop clinical practice guidelines applicable to Mexico. The expert opinion of specialists in the following areas was taken into account: gastroenterology, infectious diseases, and hepatology. A search of the medical literature was carried out on the MEDLINE, EMBASE, and CENTRAL databases through keywords related to hepatitis C treatment. The quality of evidence was subsequently evaluated using the GRADE system and the consensus statements were formulated. The statements were then voted upon, using the modified Delphi system, and reviewed and corrected by a panel of 34 voting participants. Finally, the level of agreement was classified for each statement. The present guidelines provide recommendations with an emphasis on the new direct-acting antivirals, to facilitate their use in clinical practice. Each case must be individualized according to the comorbidities involved and patient management must always be multidisciplinary. 相似文献
44.
Steve Rockman Dorit Becher Allison Dyson Sandra Koernig Adriana Baz Morelli Megan Barnden Sarina Camuglia Peter Soupourmas Martin Pearse Eugene Maraskovsky 《Vaccine》2014
In Australia, during the 2010 Southern Hemisphere (SH) influenza season, there was an unexpected increase in post-marketing adverse event reports of febrile seizures (FS) in children under 5 years of age shortly after vaccination with the CSL 2010 SH trivalent influenza vaccine (CSL 2010 SH TIV) compared to previous CSL TIVs and other licensed 2010 SH TIVs. In an accompanying study, we described the contribution to these adverse events of the 2010 SH influenza strains as expressed in the CSL 2010 SH TIV using in vitro cytokine/chemokine secretion from whole blood cells and induction of NF-κB activation in HEK293 reporter cells. The aim of the present study was to identify the root cause components that elicited the elevated cytokine/chemokine and NF-κB signature. Our studies demonstrated that the pyrogenic signal was associated with a heat-labile, viral-derived component(s) in the CSL 2010 SH TIV. Further, it was found that viral lipid-mediated delivery of short, fragmented viral RNA was the key trigger for the increased cytokine/chemokine secretion and NF-κB activation. It is likely that the FS reported in children <5 years were due to a combination of the new influenza strains included in the 2010 SH TIV and the CSL standard method of manufacture preserving strain-specific viral components of the new influenza strains (particularly B/Brisbane/60/2008 and to a lesser extent H1N1 A/California/07/2009). These combined to heighten immune activation of innate immune cells, which in a small proportion of children <5 years of age is associated with the occurrence of FS. The data also demonstrates that CSL TIVs formulated with increased levels of splitting agent (TDOC) for the B/Brisbane/60/2008 strain can attenuate the pro-inflammatory signals in vitro, identifying a potential path forward for generating a CSL TIV indicated for use in children <5 years. 相似文献
45.
《Vaccine》2017,35(45):6166-6171
For administration of multiple live attenuated vaccines, the Advisory Committee on Immunization Practices recommends either simultaneous immunization or period of at least 28 days between vaccines, due to a possible reduction in the immune response to either vaccine.The main objective of this study was to compare the immune response to measles (alone or combined with mumps and rubella) and yellow fever vaccines among infants aged 6–24 months living in a yellow fever non-endemic country who had received measles and yellow fever vaccines before travelling to a yellow fever endemic area.Subjects and methods: A retrospective, multicenter case-control study was carried out in 7 travel clinics in the Paris area from February 1st 2011 to march 31, 2015. Cases were defined as infants immunized with the yellow fever vaccine and with the measles vaccine, either alone or in combination with mumps and rubella vaccine, with a period of 1–27 days between each immunization. For each case, two controls were matched based on sex and age: a first control group (control 1) was defined as infants having received the measles vaccine and the yellow fever vaccine simultaneously; a second control group (control 2) was defined as infants who had a period of more than 27 days between receiving the measles vaccine and yellow fever vaccine.The primary endpoint of the study was the percentage of infants with protective immunity against yellow fever, measured by the titer of neutralizing antibodies in a venous blood sample.Results: One hundred and thirty-one infants were included in the study (62 cases, 50 infants in control 1 and 19 infants in control 2). Of these, 127 (96%) were shown to have a protective titer of yellow fever antibodies. All 4 infants without a protective titer of yellow fever antibodies were part of control group 1.Discussion: The measles vaccine, alone or combined with mumps and rubella vaccines, appears to have no influence on humoral immune response to the yellow fever vaccine when administered between 1 and 27 days. The absence of protective antibodies against yellow fever was observed only among infants who received both vaccines simultaneously.Conclusion: These results may support a revision of current vaccination recommendations concerning the administration of these two live attenuated vaccines either on the same day or at least 28 days apart. Our findings show no statistically significant difference if the interval between both vaccines is more than 24 h, but the immune response seems to be reduced when the two vaccines are given at the same time. 相似文献
46.
47.
《Journal of vascular and interventional radiology : JVIR》2020,31(1):108-113
PurposeTo summarize the Society of Interventional Radiology Foundation’s Research Consensus Panel development of a research agenda on prostate artery embolization (PAE).Materials and MethodsPAE for the treatment of lower urinary tract symptoms has been shown to be safe and effective in decreasing symptoms and prostate size. Lack of randomized controlled trials (RCTs) on PAE in the United States has prevented inclusion in American Urologic Association guideline recommendations for treatment of lower urinary tract symptoms resulting from benign prostatic hyperplasia. Recognizing the need for well-designed trials, the SIR Foundation funded a Research Consensus Panel to prioritize a research agenda. The panel included interventional radiologists, urologists, SIR Foundation leadership, and industry representatives. The goal of the meeting was to discuss weaknesses with current data and study design for development of US trials to report long-term outcomes data.ResultsFinal consensus on a research design could not be made because the group was split on 3 research designs: (i) RCT of PAE versus sham with crossover of the sham group. (ii) RCT of PAE versus simple prostatectomy. (iii) RCT of PAE versus holmium laser enucleation of the prostate/thulium laser enucleation of the prostate. The panel recommended a nonindustry-funded registry to obtain real-world data.ConclusionsLevel 1 data are required to be included in the American Urologic Association guidelines for treatment of benign prostatic hyperplasia. Because of concerns with all 3 study designs, the panel did not reach a consensus. Further meetings are planned with the panel to select among these research designs. 相似文献
48.
《Journal of pharmaceutical sciences》2019,108(7):2207-2237
This review describes the landscape of novel modalities such as cell and gene therapies, viruses, other novel biologics, oligomers, and emerging technologies, including modern analytics. We summarize the regulatory history and recent landmark developments in some major markets and examine specific chemistry, manufacturing, and controls (CMC) challenges, including suggestions for exploration of potential science-based approaches in support of regulatory strategy development from an industry perspective. In addition, we evaluate the economic factors contributing to patient access to innovation and discuss the impact of regulation. There is a desperate need for a consistent form of regulation where global approaches to regulatory strategies can be harmonized, and specific CMC challenges can be dealt with using the appropriate science and risk-based tools. Although these tools are well described in current guidance documents, the specifics of applicability to complex novel modalities can still result in differing regulatory advice and outcomes. The future goals for efficiently regulating innovative modalities and technologies could be aided by more regulatory harmonization, regulatory education, and industry cooperation through consortia, enabling industry to supply key information to regulators in a transparent yet well-defined manner, and utilizing mutually understood risk-benefit analyses to produce drugs with appropriate safety, efficacy, and quality characteristics. 相似文献
49.
50.